Company profile
Ideaya Biosciences, Inc.
Pipeline9 assets
- DarovasertibIDE196 / PKC / Small Molecule / Oncology1L metastatic uveal melanoma (HLA-A*02:01 negative)Phase 2/3Positive topline; NDA initiationGlobalNeoadjuvant primary uveal melanomaPhase 2/3OngoingUS
- IDE397IDE397 / MAT2A / Small Molecule / OncologyMTAP-deleted solid tumorsPhase 1OngoingUS
- IDE849IDE849 / DLL3 / ADC / OncologyDLL3-expressing solid tumors (SCLC, NEC)Phase 1OngoingUS
- IDE161IDE161 / PARG / Small Molecule / OncologyHRD solid tumorsPhase 1RecruitingUS
- IDE034IDE034 / PTK7/B7H3 / Bispecific ADC / OncologyB7H3/PTK7 solid tumors (NSCLC, CRC, breast, ovarian)Phase 1OngoingUS
- IDE892IDE892 / PRMT5 / Small Molecule / OncologyMTAP-deleted solid tumorsPhase 1OngoingUS
- IDE574IDE574 / KAT6/7 / Small Molecule / OncologySolid tumors (breast, prostate, CRC, lung)Phase 1OngoingUS
- IDE275IDE275 / Werner Helicase (WRN) / Small Molecule / OncologyMSI-high solid tumorsPhase 1OngoingUS
- IDE705IDE705 / Pol Theta (POLQ) / Small Molecule / OncologyHRD solid tumorsPhase 1OngoingUS
Latest news6 items
All newsIDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Trial Results • Phase 2/3